• 0Shopping Cart
XL-protein offers PASylation, a biological alternative to PEGylation
  • About
    • Corporate overview
    • Leadership team
  • Technology
    • Overview
    • Applications
      • Eye diseases
      • Cytokines
      • Enzymes
      • Peptides
      • Antibody fragments
      • Nanoparticles
      • In vivo imaging
      • AnimalHealth
    • PAS-Advantages
    • Intellectual property
  • Partnering
    • Partnering
  • News & Publications
    • Press Releases
    • Receive our Press Releases
    • Partner’s Press Releases
    • Key publications
    • Various publications
  • Careers
  • Contact
    • Contact
    • Imprint
    • Disclaimer
  • PAS-Shop
    • Products
    • Terms & Conditions
    • Privacy Policy
    • Shipping
  • Search
  • Menu Menu

Rentschler Biopharma and XL-protein demonstrate efficient production of a hyperactive PASylated DNase I with extended half-life

26. October 2021
Hyperactive DNase I modified with XL-protein’s PASylation®…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362021-10-26 10:22:002021-10-26 10:46:19Rentschler Biopharma and XL-protein demonstrate efficient production of a hyperactive PASylated DNase I with extended half-life

XL-protein announces the Avi-PA(S)™ MAb platform to boost the preclinical and clinical development of therapies using its PASylation® technology

12. July 2021
FREISING, GERMANY, July 12, 2021 – XL-protein GmbH, a German…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362021-07-12 13:30:002021-07-12 13:22:12XL-protein announces the Avi-PA(S)™ MAb platform to boost the preclinical and clinical development of therapies using its PASylation® technology

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

25. February 2021
NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Akari…
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362021-02-25 18:58:262021-09-10 15:01:56Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
Page 1 of 10123›»
© 2021 - All Rights Reserved for XL-protein GmbH | Imprint | Disclaimer | Data Privacy Policy | Terms & Conditions
  • Mail
Scroll to top